09/29/2026
🚨Oncology Focus: The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for Telomir-Zn to begin a first-in-human Phase 1/2 clinical trial for advanced or metastatic triple-negative breast cancer (TNBC). Preclinical studies have also shown growth inhibition in prostate cancer and human/canine osteosarcoma cell lines.